BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $10,400,453 | $10,523,457 | $13,499,457 | $12,533,922 |
| - Cash | $1,250,108 | $1,213,816 | $1,048,803 | $942,842 |
| + Debt | $596,663 | $603,866 | $601,959 | $602,712 |
| Enterprise Value | $9,747,008 | $9,913,507 | $13,052,613 | $12,193,792 |
| Revenue | $776,133 | $825,410 | $745,145 | $747,313 |
| % Growth | -6% | 10.8% | -0.3% | – |
| Gross Profit | $636,048 | $675,320 | $593,587 | $611,174 |
| % Margin | 82% | 81.8% | 79.7% | 81.8% |
| EBITDA | -$5,258 | $319,110 | $263,021 | $195,496 |
| % Margin | -0.7% | 38.7% | 35.3% | 26.2% |
| Net Income | -$30,744 | $240,532 | $185,686 | $124,943 |
| % Margin | -4% | 29.1% | 24.9% | 16.7% |
| EPS Diluted | -0.16 | 1.23 | 0.95 | 0.64 |
| % Growth | -113% | 29.5% | 48.4% | – |
| Operating Cash Flow | $368,685 | $185,271 | $174,394 | $185,627 |
| Capital Expenditures | -$28,447 | -$17,101 | -$16,768 | -$20,299 |
| Free Cash Flow | $340,238 | $168,170 | $157,626 | $165,328 |